The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that adults over 65 and immunocompromised people get ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

How bad is this news for Novavax? Let's find out. Image source: Getty Images.

On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

In the closing of the recent trading day, Novavax (NVAX) stood at $10, denoting a -1.19% change from the preceding trading day.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...